FDA approved first targeted therapy for subset of non-mmall cell lung cancer
On May 21, 2021, the FDA approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA granted approval of Rybrevant to Janssen Pharmaceutical Companies of Johnson & Johnson.
Tags:
Source: U.S. Food and Drug Administration
Credit:
